Komori
Share Issuance and Disposal4575CanBas Co.,Ltd.Pharmaceuticals

Notice Regarding the Substantial Exercise of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Clause)

Of the Series 22 Stock Acquisition Rights, 2,275 were exercised between 2 November and 17 November 2026, and 227,500 new shares were issued. The number of unexercised Stock Acquisition Rights after the exercises was 17,725.

Worth reading
67In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
227500
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Significant exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数227,500Shares

227,500 new shares

発行済株式総数

Exercise ratio relative to total issued: 11.38% (2,275 Stock Acquisition Rights exercised)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
With an exercise price adjustment clause. The exercise prices during the period were ¥689, ¥669, ¥651, ¥614, ¥612, ¥633, ¥652, ¥664, ¥653, ¥648 and ¥661.
Number of Stock Acquisition Rights
Total issued: 20,000; unexercised balance: 17,725 (20,000 at the end of the previous month)
Most recent equity financing
Series 22 Stock Acquisition Rights issued on 30 October 2026 (with an exercise price adjustment clause), and Series 23 and Series 24 Stock Acquisition Rights (with an option to adjust the exercise price)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalSignificant exercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of227,500 new shares
Dilution RateExercise ratio relative to total issued: 11.38% (2,275 Stock Acquisition Rights exercised)
Total number of issued shares19,713,655 shares (including 10,598 treasury shares) → Not disclosed
Exercise priceWith an exercise price adjustment clause. The exercise prices during the period were ¥689, ¥669, ¥651, ¥614, ¥612, ¥633, ¥652, ¥664, ¥653, ¥648 and ¥661.
Number of Stock Acquisition RightsTotal issued: 20,000; unexercised balance: 17,725 (20,000 at the end of the previous month)
Most recent equity financingSeries 22 Stock Acquisition Rights issued on 30 October 2026 (with an exercise price adjustment clause), and Series 23 and Series 24 Stock Acquisition Rights (with an option to adjust the exercise price)
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This disclosure reports the fact of the large-scale exercise; the company has provided no explanation of the reasons for the exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Substantial Exercise of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Clause) | CanBas Co.,Ltd. (4575) timely disclosure | Komori